Insulet Corporation $PODD Stock Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 144.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,356 shares of the medical instruments supplier’s stock after acquiring an additional 14,996 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Insulet were worth $3,308,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. State of Wyoming lifted its position in Insulet by 34.6% in the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 73 shares during the period. Optas LLC lifted its stake in Insulet by 8.8% in the 1st quarter. Optas LLC now owns 1,059 shares of the medical instruments supplier’s stock valued at $222,000 after buying an additional 86 shares in the last quarter. American Trust boosted its stake in shares of Insulet by 8.6% during the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock worth $248,000 after purchasing an additional 93 shares during the last quarter. Basecamp Wealth Advisors LLC raised its holdings in Insulet by 48.3% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 102 shares during the last quarter. Finally, Elevation Wealth Partners LLC increased its stake in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 104 shares during the last quarter.

Insulet Trading Up 2.6%

NASDAQ PODD opened at $153.61 on Tuesday. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company’s 50 day moving average price is $141.02 and its 200 day moving average price is $179.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The firm has a market capitalization of $10.65 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 1.17 and a beta of 1.11.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same period in the previous year, the company posted $1.17 earnings per share. Insulet’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. downgraded shares of Insulet from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $275.00 to $152.00 in a research note on Thursday, August 6th. UBS Group dropped their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a report on Thursday, August 6th. Evercore set a $180.00 target price on Insulet in a research report on Monday, July 6th. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Finally, Jefferies Financial Group lowered their price target on Insulet from $275.00 to $190.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Insulet has a consensus rating of “Hold” and an average target price of $186.68.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.